4D Molecular Therapeutics (FDMT) Starts Phase 3 4SIGHT Trial in DME

4D Molecular Therapeutics initiated 4SIGHT, a Phase 3 trial of 4D-150 in diabetic macular edema, with first patients enrolled and FDA RMAT designation noted.Material DetailsContext by AI AnalystThis is a late-stage development milestone extending 4D-150 into a second Phase 3 indication alongside we…